A global Deloitte survey of healthcare and life sciences executives reveals that tariffs and evolving pricing policies are reshaping strategic planning. Nearly two-thirds expect moderate to major impacts on their commercial outlook. While R&D spending remains steady, firms face challenges adapting supply chains and negotiating pricing. Only 10% have restructured operations, signaling opportunities for agility in a complex policy environment. U.S. companies particularly emphasize scenario planning to navigate uncertainties.